The short version
Semaglutide and tirzepatide are both injectable medications commonly discussed in weight management, and both act on the GLP-1 receptor. Tirzepatide additionally acts on the GIP receptor. Beyond that mechanism difference, they're administered similarly — weekly injection, gradual dose adjustment, provider-guided. Which one (if either) makes sense for a given person is a clinical decision, not a matter of picking the "better" option off a comparison chart.
Side by side
Swipe to see every column
| Semaglutide | Tirzepatide | |
|---|---|---|
| Receptor(s) targeted | GLP-1 | GLP-1 and GIP |
| Typical administration | Weekly injection | Weekly injection |
| Dosing approach | Gradual increase, provider-guided | Gradual increase, provider-guided |
What's actually different
The clearest structural difference is the additional GIP-receptor activity in tirzepatide. Researchers have studied whether that additional pathway changes outcomes, tolerability, or side effects compared to single-pathway GLP-1 medications — but how any individual responds to either medication varies, and general comparisons don't predict an individual result.
Practically, for most people, the day-to-day experience is similar: both are self-administered injections on a weekly schedule, both involve a gradual dose increase managed by a provider, and both are typically paired with nutrition and activity changes as part of a broader plan.
Questions worth bringing to a provider
- What would you recommend for someone with my health history, and why?
- How does dosing typically progress for each option?
- What side effects are most commonly discussed with each?
- Does my insurance treat these differently?
For a fuller list, see questions to ask a healthcare provider about weight-loss medication.
Where to go from here
For a deeper look at each medication individually, see semaglutide explained and tirzepatide explained. You can also explore treatment options to see how Benthos approaches each.